Retrospective Cohort Study
Copyright ©The Author(s) 2017.
World J Transplant. Feb 24, 2017; 7(1): 34-42
Published online Feb 24, 2017. doi: 10.5500/wjt.v7.i1.34
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Patient survival in patients with delayed graft function. The 1, 3 and 5 year patient survival post-transplant: A: Overall patient survival: 96.3%, 87.2% and 82.5% in the DGF group and 97.9%, 95.0% and 94.2% in the PGF group, P < 0.01; B: Patient survival censored at the time of allograft failure: 98.4%, 90.2% and 87.2% in the DGF group and 97.9%, 95.7% and 94.9%, P = 0.047. DGF: Delayed graft function; PGF: Primary graft function.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Censored allograft survival. Censored allograft survival in the DGF group was 90.3%, 84.7% and 77.9% at 1, 3 and 5 years compared with 99.0%, 95.5% and 90.2% in the PGF group, P < 0.001. DGF: Delayed graft function; PGF: Primary graft function.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Allograft survival by donor type and delayed graft function. Allograft survival in the DBD and DCD donors with PGF was significantly higher than the recipients of DBD and DCD kidneys with DGF, with an allograft survival of 90.3%, 90.7%, 75.3% and 65.8% respectively, P = 0.0016. DGF: Delayed graft function; PGF: Primary graft function; DBD: Brain death; DCD: Circulatory death.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Three month and overall rejection free survival by induction agent and delayed graft function. Rejection free survival, censored for DSA+ in patients with alemtuzumab induction and PGF (C-PGF), alemtuzumab induction and DGF (C-DGF), IL2RA induction and PGF (IL2RA-PGF) and IL2RA induction and DGF (IL2RA-DGF) at A: 3 mo: 93.0%, 92.9%, 92.5% and 77.8% respectively, P = 0.03 and B: 5 year: 76.4%, 71.5%, 76.5% and 70.7%, P = 0.75. DGF: Delayed graft function; PGF: Primary graft function.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Allograft function according to delayed graft function or primary graft function. Mean serum creatinine was 203.4 ± 120.0, 172.3 ± 86.6, 161.9 ± 74.9, 167.2 ± 86.1 and 149.6 ± 59.4 μmol/L at 1, 6, 12, 36, 60 mo post-transplant in the DGF group compared with 132.4 ± 48.6, 133.8 ± 56.7, 127.8 ± 43.6, 138.4 ± 47.7 and 143.0 ± 65.2 4 μmol/L in the PGF group; giving a P value of < 0.01 at 1 to 12 mo, a P value of 0.015 at 36 mo and 0.70 at 60 mo. DGF: Delayed graft function; PGF: Primary graft function.